stockportfolio.pro
Stocks / INDV vs TVTX
INDV vs TVTX
Indivior Pharmaceuticals, Inc. and Travere Therapeutics, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Indivior Pharmaceuticals, Inc. (INDV) | Travere Therapeutics, Inc. (TVTX) | |
|---|---|---|
| Market cap | $4.5B | $4.5B |
| Revenue (latest FY) | $1.24B | $490.73M |
| Net income (latest FY) | $210.00M | $-25.55M |
| Revenue growth (5y CAGR) | 11.2% | 19.9% |
| Net margin | 16.9% | -5.2% |
| Return on equity | -214.3% | -22.2% |
| P/E ratio | 19.5 | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 2 | 0 |
| Positive free cash flow | No | No |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open INDV — free Open TVTX — freeFrequently asked questions
Which is bigger, INDV or TVTX?
Indivior Pharmaceuticals, Inc. is larger by market capitalization — $4.5B versus $4.5B.
Which grows faster, INDV or TVTX?
Over the last five fiscal years, Travere Therapeutics, Inc. grew revenue faster — 19.9%/yr versus 11.2%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.